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High-mobility-group box protein 1 A box reduces
development of sodium laurate-induced
thromboangiitis obliterans in rats
Xiangqian Kong, MD, Hai Yuan, MD, Xuejun Wu, MD, Jingyong Zhang, MD, Hua Zhou, MD,
Maohua Wang, MD, Yang Liu, MD, and Xing Jin, MD, Ji’nan, China
Objective: High-mobility-group box protein 1 (HMGB1), as a late mediator of inflammation, plays a key role in
inflammatory responses by inducing and extending the production of proinflammatory cytokines. The effect of HGMB1
in the inflammatory disease thromboangiitis obliterans (TAO) is unknown. We aimed to investigate the role of HMGB1
in sodium laurate-induced TAO in rats.
Methods: Male Wistar rats were randomly divided into five groups (n  8 each) for treatment: normal, sham-operated,
TAO model, and low-dose (15 mg/kg) or high-dose (30 mg/kg) recombinant A box (rA box) infection (administered
intraperitoneally once daily for 15 days). The TAOmodel was induced by sodium laurate and graded by gross appearance
on day 15 after femoral artery injection. Histologic changes were measured by histopathology in rat femoral arteries.
Plasma levels of HMGB1, thromboxane B2, 6-keto-prostaglandin F1-, and blood cell counts and blood coagulation
levels were measured. Expression of HMGB1, receptor for advanced glycation end-products (RAGE), interleukin-6,
intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 was assessed by immunohistochemistry and
immunofluorescence, Western blot analysis, and quantitative reverse-transcription polymerase chain reaction.
Results: The typical signs and symptoms of TAO were observed on day 15 after sodium laurate injection. The expression
ofHMGB1, RAGE, interleukin-6, intercellular adhesionmolecule-1, and vascular cell adhesionmolecule-1 wasmarkedly
increased in rat femoral arteries. Plasma levels of HMGB1 and thromboxane B2 were elevated, but the level of
6-keto-prostaglandin F1- was decreased. Blood was in a hypercoagulable state, and prothrombin, thrombin, and
activated partial thromboplastin times were all significantly shortened, whereas fibrinogen level was increased in TAO rats
compared with sham-operated rats. These effects were terminated by the HMGB1 antagonist rA box.
Conclusions:HMGB1 is involved in the inflammatory state in amodel of TAO induced by sodium laurate in rats, probably
via its receptor RAGE. As the antagonist of HMGB1, rA box can attenuate the development of TAO, which may be a
potential therapeutic target for the treatment of TAO. (J Vasc Surg 2013;57:194-204.)
Clinical Relevance: Thromboangiitis obliterans (TAO), or Buerger disease, is a segmental nonatherosclerotic inflamma-
tory disorder. Patients with Buerger disease have a lower quality of life because of intermittent claudication, rest pain,
ulcers, and superficial thrombophlebitis. The specific etiology and pathologic mechanisms remain not elucidated.
High-mobility-group box protein 1, as a late mediator of inflammation, plays a key role in inflammatory responses to
tissue injury and infection by inducing and extending the production of proinflammatory cytokines. Here, we explored
the role of high-mobility-group box protein 1 in rat model of TAO, discovering a new damage marker in TAO. We also
investigated the unique role of recombinant A box in the prevention and treatment of TAO.
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rThromboangiitis obliterans (TAO), also known as
Buerger disease, is a segmental nonatherosclerotic inflam-
matory disorder that involves primarily small and medium
arteries and veins of the extremities.1 Patients with this
disease have a lower quality of life because of intermittent
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194laudication, rest pain, ulcers, and superficial thrombophle-
itis.2 Recent studies showed the expression of intercellular
dhesion molecule-1 (ICAM-1), vascular cell adhesion
olecule-1 (VCAM-1), E-selectin, and tumor necrosis fac-
or (TNF)- was increased in endothelium and inflamma-
ory cells in the thickened intima in all TAO patients.3 The
cute inflammation involving all layers of the vessel wall and
cclusive inflammatory thrombosis in acute-phase lesions
ed TAO to be classified as an inflammatory disease.4 How-
ver, the specific etiology and pathologic mechanisms for
AO remain unclear. In the sodium laurate–induced arte-
ial occlusive disease model in rats, the injected sodium
aurate is postulated to cause endothelial cell damage that
ay lead to the aggregation of platelets in peripheral vas-
ular beds.5 The progression in this model resembles that
eported in TAO patients.6
High-mobility-group box 1 (HMGB1), a highly con-
erved nonhistone protein, presents in the nuclei. During
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Volume 57, Number 1 Kong et al 195cell activation and cell death, HMGB1 can translocate to
the cytoplasm and extracellular space for proinflammatory
effects via interaction with two types of receptors on the cell
surface: Toll-like receptor (TLR) and receptor for advanced
glycation end-products (RAGE).7 RAGE, a transmem-
brane, pattern-recognizing receptor expressed in most tis-
sues and present on a wide range of cells, has a high affinity
with HMGB1.8,9 HMGB1 interaction with these receptors
transduces intracellular signals and mediates cellular re-
sponses, including chemotactic cell movement and release
of proinflammatory cytokines (eg, TNF- and interleukin
[IL]-6), adhesion molecules (eg, ICAM-1 and VCAM-1)
in vitro, and causes fever, epithelia barrier dysfunction,
endothelial dysfunction, and acute inflammation in vivo.10
Elevated levels of HMGB1 as a proinflammatory cytokine
in serum and tissues occurs during sterile tissue injury, such
as in arthritis, and ischemia-reperfusion injury,11,12 and
during infection, such as lethal endotoxemia and sep-
sis.13,14
HMGB1 has two DNA-binding motifs: A and B box.
Structure–function analyses demonstrated that the active
cytokine domain of HMGB1 is localized to the DNA-
binding B box, whereas the A box competes with HMGB1
for binding sites and attenuates the biologic function of the
full-length HMGB1. Recently, recombinant A (rA) box, as
a specific antagonist of HMGB1, was found protective in
multi-established preclinical inflammatory disease mod-
els.15-17 Nevertheless, rA box has not been administered in
humans, and its safety still needs to be evaluated in clinical
trials.
We therefore hypothesized that HMGB1 might be a
potent proinflammatory factor in TAO and that rA box
would inhibit the progression of the disease by attenuating
the release of inflammatory factors and inflammation-
induced thrombotic tendencies. In this study, we explored
the role of HMGB1 in sodium laurate-induced TAO rats.
We also investigated whether rA box plays a unique role in
the treatment of TAO.
METHODS
Animals. All animal care and procedures in this inves-
tigation conformed to the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health Publica-
tion No. 85-23, National Academy Press, Washington DC,
revised 1996). Experimental protocols were approved by
the Ethical Review Board of Shandong University. Male
Wistar rats (200-250 g) were provided by Shandong Uni-
versity Experimental Animal Center. Water and food were
given ad libitum.
Preparation for rA box protein. The rA box protein
was prepared as described.18 Briefly, recombinant pro-
karyon expression vector pQE-80L/DHFR/HMGB1 A
box (Third Military Medical University, Chongqing,
China) was transformed into Escherichia coli bacillus M15
and incubated in Luria-Bertani culture media for 5 to 7
hours at 37°C. Fusion protein expression was induced by
the addition of 1 mM isopropyl thiogalactose at optical
density 600 between 0.6 and 0.8. Bacteria were collected by centrifuging at 4000 g at 4°C for 15 minutes and
ltrasonically shattered to obtain supernatant fluid. Then,
0% nickel-nitrilotriacetic acid slurry (1 mL) and phenylm-
thyl sulfonyl fluoride were added. The mixture was inten-
ively centrifuged at 200 rpm at 4°C for 1 hour and then
urified by chromatography separation and dialysis desali-
ation. Proteins were further purified in a polymyxin B
olumn (Pierce, Rockford, Ill).
Experimental groups and protocol. Male Wistar rats
ere randomly divided into five groups (n  8 each) for
reatment: normal, sham-operated, TAO model, and rA
ox infection at 15 mg/kg (low dose) and 30 mg/kg (high
ose). Sodium laurate-induced TAO was prepared as de-
cribed.5 Briefly, rats were anesthetized with 10% (w/v)
hloral hydrate (3.5 mL/kg intraperitoneally). The left
ind leg was shaved, and the femoral artery was exposed by
urgical incision. Sodium laurate (0.1 mL; Sigma-Aldrich,
t. Louis, Mo) solution (10 mg/mL in normal saline, pH
.0) was injected into the left femoral artery. The sham-
perated group was treated with normal saline as a vehicle.
ll groups underwent the surgical procedure except the
ormal group. rA box (15 or 30 mg/kg) or phosphate-
uffered saline (PBS) vehicle was administered intraperito-
eally 2 hours after the sodium laurate injection and once a
ay for the next 14 days. Buprenorphine (0.05 mg/kg/d
ntraperitoneally) was used as analgesia. At the end of the
xperiment, a blood sample was drawn from the common
arotid artery for biochemical analysis, and femoral arteries
ere collected for homogenate and histologic examination.
Main pathologic signs. The gross appearance in rat
ind legs was checked daily after the operation. The degree
f the disease on day 15 was graded as described19: 0,
ormal appearance; I, change in nail color; II, change in
igit color; III, gangrene of digit; IV, loss or mummifica-
ion of digit.
Hematology. Blood cell counts (XE-2100) and blood
oagulation (CA-7000; SysmexMedical Electronics, Kobe,
apan) were measured by the clinical laboratory in the
rovincial Hospital affiliated to Shandong University.
Plasma analysis. Plasma levels of HMGB1 (Shino-Test
orp, Tokyo, Japan), thromboxane B2 (TXB2; Cayman
hemical, Ann Arbor,Mich), and 6-keto-prostaglandin F1-
6-K-PGF1-) (Enzo Life Sciences Inc, Farmingdale, NY)
ere measured by enzyme-linked immunosorbent assay
ELISA) kits.
Histologic evaluation, immunohistochemistry, and
mmunofluorescence. Rat femoral arteries were fixed in
0% neutral formalin for at least 24 hours, paraffin-
mbedded, cut into 5-m slices, and deparaffinized. He-
atoxylin and eosin staining was performed by a standard
rotocol. Sections were incubated overnight with 50 L of
rimary antibody for HMGB1 (3935; Cell Signaling Tech-
ology, Danvers, Mass), IL-6 (sc-57315; Santa Cruz Bio-
echnology, Santa Cruz, Calif), ICAM-1 (sc-8439), and
CAM-1 (sc-1504) after blocking, then washed and incu-
ated with the appropriate secondary antibody for 1 hour.
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January 2013196 Kong et alSlides were stained with 3,3-diaminobenzidine. Sections
were counterstained with hematoxylin. The remaining sec-
tions were used for immunofluorescence with the following
Fig 1. A, Gross appearance of rat paws; (B) hem
magnification,100) in (a) normal (nor), (b) sham-opera
(d) low-dose (rA box-LD) and (e) high-dose (rA box-LD)
area ratio of thrombus of femoral arteries on day 15 after
error of the mean (error bars). **P  .01 vs sham-opera
Table I. Specific sense and antisense primers for real-time
analysis
Primer Sense sequence
HMGB-1 GAGATCCTAAGAAGCCGAGA CTT
RAGE ACCCTTAGCTGGCACTTGGATG ATC
ICAM-1 AGAAGGACTGCTTGG GGA A CCT
VCAM-1 CTGACCTGCTCAAGTGATGG GTG
IL-6 AATCTGCTCTGGTCTTCTGGAG GTT
GAPDH CTCAAGATTGTCAGCAATGC CAG
GAPDH,Glyceraldehyde-3-phosphate dehydrogenase;HMGB1, high-mobi
RAGE, receptor for advanced glycation end-products; VCAM-1, vascular cantibodies: RAGE (sc-5563) and cluster of differentiation l1 (sc-31045). After incubation with the appropriate Alexa
luor 488/546-conjugated secondary antibodies (Invitro-
en, Carlsbad, Calif), the sections were observed by confocal
lin and eosin staining of femoral arteries (original
ham), (c) thromboangiitis obliterans (TAO) model, and
mbinant A (rA) box-treated groups; and (C) data for the
m laurate injection. Data are shown as mean standard
roup. #P  .05 vs TAO model group.
titative reverse-transcription polymerase chain reaction
Antisense sequence
Size Annealing temp
(bp) (°C)
CATCCTCTTCATCC 595 52
GAGCCACTTATGCT 391 64
GCGGTAATA GGTG 331 58
CCCTCTTTG ACGCT 260 60
TGGTCTTGGTCCTTAG 363 62
GCCCTTTAGTGGGC 394 58
oup box 1; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6;
esion molecule.atoxy
ted (s
reco
sodiuquan
CCT
GGA
CTG
TCT
GGA
GAT
lity-graser scanning microscopy (Leica, Solms, Germany).
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Volume 57, Number 1 Kong et al 197Fig 2. A, Plasma levels of high-mobility-group box protein 1 (HMGB1) are shown for normal (nor), sham-operated
(sham), and thromboangiitis obliterans (TAO) model and the low-dose (rA box-LD) and high-dose (rA box-HD)
recombinant A (rA) box-treated groups. Results are means standard error of the mean (error bars); n 8. **P .01
vs sham-operated group. #P  .05 vs TAO model group. B, Representative micrographs of HMGB1 in rat femoral
arteries by 3,3-diaminobenzidine staining and (C) double immunofluorescent staining for receptor for advanced
glycation end-products (RAGE) and cluster of differentiation 31 (CD 31) are shown for (a) nor, (b) sham, (c) TAO,
and (d) rA box-LD and (e) rA box-HD groups.
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January 2013198 Kong et alWestern blot analysis. Arterial tissue protein was ex-
tracted by the cell lysis buffer (Beyotime Institute of Bio-
technology, Shanghai, China) after removal of thrombus.
Protein extracts were separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and electrically
transferred to polyvinylidene difluoride membranes, which
were blocked with 5% nonfat dry milk in PBS-0.05% Tween
20 for 1 hour, then the primary antibody for HMGB1
(3935; Cell Signaling Technology), RAGE (sc-5563), IL-6
(sc-57315), ICAM-1 (sc-8439), VCAM-1 (sc-1504), and
-actin (sc-81178) was applied overnight at 4°C. The
membranes were incubated with appropriate secondary
antibodies for 1 hour at 37°C and visualized by enhanced
chemiluminescence assay (Thermo Fisher Scientific, Rock-
ford, Ill). Band concentration was calculated by quantifica-
tion of optical density.
Quantitative real-time reverse-transcription poly-
merase chain reaction. Total RNA was extracted from
femoral arteries by use of the RNeasy Mini kit (Qiagen,
Hilden, Germany) after removal of thrombus. After purifi-
cation, RNA was converted to complimentary (c)DNA by
the use of polymerase chain reaction (PCR) (RNA PCR
Core Kit, Applied Biosystems, Foster City, Calif). Real-
time quantitative reverse-transcription PCR was performed
on a LightCycler (Roche, Mannheim, Germany) as de-
scribed,20 with 2 L of cDNA, 0.2 mol of each primer,
and 10 L of SYBRGreen PCRMaster Mix in each PCR at
a final volume of 20 L. The primers are summarized in
Table I. Data were analyzed with the comparative threshold
cycle relative-quantification method, and the expression of
target genes was normalized to that of glyceraldehyde-3-
phosphate dehydrogenase as a constitutive control.
Statistical analysis. Data are expressed as means 
standard error of the mean and were analyzed by SPSS 13.0
software (SPSS Inc, Chicago, Ill). Significant differences
after one-way analysis of variance tests were measured with
Student–Newman-Keuls multiple comparison methods.
The Kruskal-Wallis H test was used to compare the gross
appearance among groups. P  .05 was considered statis-
tically significant.
RESULTS
Rat TAOmodel induced by sodium laurate injection.
The rat model of TAO induced by sodium laurate is a
widely accepted model.5,21,22 In our study, the left hind
paw of rats went pale 1 or 2 minutes after sodium laurate
injection. On day 15, TAO rats (Fig 1, Ac) but not sham-
operated or normal rats (Fig 1, Aa and Ab) showed typical
signs and symptoms of TAO. Stained sections of TAO rats
showed thrombi that resulted in narrowing or complete
occlusion of the vessel lumen (Fig 1, Bc).
Elevated HMGB1 and RAGE expression in TAO
rats. Compared with sham-treated animals, TAO rats
showed increased plasma HMGB1 level (P  .01; Fig 2,
A), with no difference between the normal and sham-
operated group. HMGB1 was expressed in intima and
media in TAO rats (Fig 2, Bc) and appeared frequently
within the cytoplasm and was diffusely distributed within iesions, which probably reflected secreted HMGB1. Com-
ared with sham-operated rats, TAO rats showed increased
xpression of RAGE mainly in the intima (Fig 2, C) and
ncreased protein expression of HMGB1 and RAGE in
emoral artery lysates (P  .01; Fig 3, A and B). The
essenger (m)RNA levels of HMGB1 and RAGE were
ignificantly increased in femoral arteries of TAO compared
ith normal and sham-operated rats (Fig 3, C).
Effect of rA box on local pathologic signs in TAO
ats. TAO rats were administered rA box to determine
hether it plays a protective role. TAO rats showed severe
schemia, which was markedly decreased with rA box injec-
ion (Fig 1, Ad and Ae). The gross appearance of the rat
ind legs was evaluated on day 15. The lesion values were
ignificantly higher in TAO rats than in sham-operated rats
nd were significantly attenuated dose-dependently in rats
hat received low-dose or high-dose rA box injection com-
ared with TAO rats (Table II). Moreover, no thrombus
ccurred in femoral arteries of the sham group (Fig 1, Bb),
hereas TAO rats showed tissue adhesion, mild lympho-
yte infiltration, and various thrombi in femoral arteries
Fig 1, Bc). The low-dose rA box mildly and high-dose rA
ox significantly reduced the levels and area of thrombus
Fig 1, Bd, Be, and C).
Effect of rA box on the expression of HMGB1 and
AGE in TAO rats. To further confirm the protective
echanisms of rA box, ELISA showed that plasma
MGB1 level decreased with high-dose rA box injection
ompared with TAO rats (P .05; Fig 2, A). Immunohis-
ochemical and immunofluorescence staining showed a
arked reduction of HMGB1 and RAGE expression in the
ascular wall with high-dose rA box injection compared
ith TAO rats (Fig 2, Be and Ce). Low-dose injection
ecreased their expression slightly (Fig 2, Bd and Cd).
hese results were consistent with the protein and mRNA
xpression of HMGB1 and RAGE analyzed by Western
olt and quantitative reverse-transcription PCR (Fig 3).
hus, high-dose rA box attenuated the gross appearance of
AO by reducing the expression of HMGB1 and RAGE.
Effect of rA box on the expression of IL-6, ICAM-1
nd VCAM-1 in TAO rats. Elevated IL-6, ICAM-1, and
CAM-1 levels are found in various inflammatory re-
ponses, including TAO.3,22,23 HMGB1 can also activate
acrophage and endothelial cells to release IL-6, ICAM-1,
nd VCAM-1.24,25 Protein staining and levels of IL-6,
CAM-1, and VCAM-1 in femoral arteries were higher in
AO rats than in sham-operated rats (P .05; Fig 4,A-C),
hich agreed with previous findings. Treatment with high-
ose but not low-dose rA box reduced the levels of IL-6,
CAM-1, and VCAM-1 significantly (P .05; Fig 4,A-C).
RNA levels were similar to levels for protein (Fig 4, D).
herefore, rA box inhibited HMGB1 to decrease the ex-
ression of inflammatory mediators in TAO rats.
Effects of rA box on hematology of TAO rats. To
urther analyze the effects of rA box on TAO rats, we
nvestigated blood cell counts and blood coagulation.
lood platelet count was markedly higher in TAO rats than
n sham-operated rats (P  .05; Table III, A). Blood
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 1 Kong et al 199Fig 3. Western blot and reverse transcription polymerase chain reaction analysis of protein and messenger RNA levels
of high-mobility-group box protein 1 (HMGB1) and receptor for advanced glycation end-products (RAGE) in femoral
arteries from normal (nor), sham-operated (sham), thromboangiitis obliterans (TAO) model, and low-dose (rA
box-LD) and high-dose (rA box-HD) recombinant A (rA) box-treated rats. A, Representative Western blot of protein
levels of HMGB1 and RAGE (-actin as a control). B, Summary data for the rat groups are presented as means 
standard error of the mean (error bars); n 8. **P .01 vs sham-operated group. #P .05 vs TAOmodel group. C,
The relative messenger RNA levels of HMGB1 and RAGE are presented as means standard error of the mean (error
bars); n  8. **P  .01 vs sham-operated group. #P  .05 vs TAO model group.
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January 2013200 Kong et alplatelet count was slightly decreased with low-dose rA box
(P  .05) and greatly decreased (P  .05) with high-dose
treatment compared with TAO rats. However, counts of
red blood cells, leukocytes, and neutrophils did not differ
among the groups (P .05). Prothrombin, thrombin, and
activated partial thromboplastin times were all significantly
shortened, and the fibrinogen level was increased in TAO
rats compared with sham-operated rats (P  .05). The
values reversed to almost normal with high-dose rA box
treatment (P  .05), with the effect of low-dose rA box
relatively weak (Table III, B).
Effects of rA box on plasma levels of TXB2 and
6-K-PGF1- and TXB2/6-K-PGF1- ratio in TAO
rats. TXB2 and 6-K-PGF1- are the stable metabolites of
TXA2 and prostacyclin (PGI2), which, respectively, in-
duces and inhibits platelet aggregation. We found the
plasma level of 6-K-PGF1 was lower and the levels of
TXB2 and TXB2/6-K-PGF1- ratio were markedly higher
in TAO rats than in sham-operated or normal rats (Fig 5).
However, rA box treatment increased the 6-K-PGF1-
level and decreased the TXB2 level and TXB2/6-K-
PGF1- ratio with low-dose and high-dose rA box treat-
ment compared with TAO rats (P  .05).
DISCUSSION
TAO is a nonatherosclerotic segmental inflammatory
disease of small and medium distal limb vessels of predom-
inantly young male smokers.26 Although the disease was
first described almost 130 years ago, the etiology, patho-
genesis, and treatment of TAO are still unresolved.27
HMGB1 has been identified as a proinflammatory media-
tor, and because of its proinflammatory and immunostimu-
latory properties, it may contribute to the pathogenesis of
multiple chronic inflammatory and autoimmune diseases
by binding its receptor RAGE.17,28 HMGB1 is released in
response to proinflammatory stimuli and induces the pro-
duction of inflammatory mediators by macrophages and
neutrophils. Moreover, HMGB1 is also an activator of
endothelial cells, leading to the upregulation of the adhe-
sion molecules24,29 found in the thickened intima in TAO
patients.3 However, no report has demonstrated the poten-
Table II. Grade of local pathologic signs in
thromboangiitis obliterans (TAO) rats
Group
Grade of lesion
P0 I II III IV
Normal 8 0 0 0 0
Sham operated 8 0 0 0 0
TAO model 0 1 1 4 2 .01a
rA box treatment
Low dose 0 2 2 3 1 .05b
High dose 1 3 2 2 0 .01b
rA, Recombinant A box.
aVs sham-operated group.
bVs TAO model group.tial role of HMGB1 in TAO. tIn this study, sodium laurate-induced rats were used as
TAO model, which has been used to study human TAO
isease because the injection of sodium laurate into the rat
emoral artery imitates signs and symptoms in TAO pa-
ients.5,6,21,22 Here, after injection of sodium laurate, most
AO rats showed typical symptoms of ischemia and vascu-
itis in the lower limb, and the femoral artery was structur-
lly changed with thrombi, recanalization, and injury of
ndothelial cells. Results from our study agree with previ-
us observations.6,22,30 Meanwhile, the TAO rats were
ound to have significantly elevated levels of HMGB1 in
lasma and tissues, and protein and mRNA levels of
MGB1 and RAGE in femoral arteries were increased in
AO rats compared with the sham-operated rats. Although
he receptors of HMGB1 include RAGE and TLRs,
eceptor-binding studies revealed that HMGB1 has higher
ffinity with RAGE,9 and recent studies suggest that
MGB1 as a regulator and inducer plays an essential role in
AGE-dependent inflammation.31,32 Thus, HMGB1
akes part in TAO, which is mediated at least in part by
AGE.
Anti-HMGB1-based therapy using HMGB1 inhibitors
as shown beneficial effects in HMGB1-involved diseases
uch as sepsis, ischemia-reperfusion injury, and rheumatoid
rthritis.12,15-17 The antagonists of HMGB1 include neu-
ralizing anti-HMGB1 antibody, A box, and the anti-
nflammatory agents ethyl pyruvate and sodium butyrate. A
ox, a specific blockade for endogenous HMGB1, has
unctional antagonism of extracellular HMGB1 cytokine
ctivity and interaction with RAGE, so purified A box has a
otential role in the clinical treatment of inflammatory
iseases, where an excessive amount of HMGB1 is pro-
uced. As mentioned above, the treatment with rA box is
afe, effective, and has no side effects.15-17 We chose high
nd low doses of rA box in rats and grouped rats according
o our previous study and other references to observe the
ffect of rA box in TAO rats but not in normal rats, in which
he expression of HMGB1 was normal.17,18,33
As we expected, rA box significantly reduced the visible
igns of ischemia and levels and area of thrombus in TAO
ats. HMGB1 in plasma, the protein and mRNA levels of
MGB1, and levels of RAGE in the femoral artery wall
everted to almost normal levels with rA box treatment.
he inhibitory effect of rA box onHMGB1 agrees with our
revious findings and results of acute cardiac allograft re-
ection.18,34 RAGEmay be decreased with the reduction of
ts ligand. That high-dose rA box could almost completely
everse but low-dose rA box only partially reversed the
ffects of HMGB1 suggests that the protective role of rA
ox may be dose-dependent.
IL-6 acts as a proinflammatory cytokine, and ICAM-1
nd VCAM-1 are two key inflammatory adhesion molecules
hat could be secreted by HMGB1-stimulating macrophage
nd endothelial cells.24,25 HMGB1 antagonists can reduce
heir release.35,36 In TAOpatients, the expression of IL-6 and
ell adhesion molecules in inflammatory and endothelial cells
nduced by proinflammatory cytokines allows cells interac-
ions to occur, leading to inflammatory cell adhesion, activa-
T
i
o
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feedback–amplified, probably due toHMGB1 and finally lead
to endothelial cell damage. We found increased expression of
Fig 4. Immunohistochemistry, Western blot, and rever
and messenger RNA levels of interleukin-6 (IL-6), inte
adhesion molecule-1 (VCAM-1) in femoral arteries from
angiitis obliterans (TAO) model, and (d) low-dose (rA b
box-treated rats. A, Representative photomicrographs
3,3-diaminobenzidine staining. B, Representative West
(-actin as a control). C, Summary data for rat groups p
n 8. *P  .05 vs sham-operated group. **P  .01 vs s
.01 vs TAO model group. D, The relative messenger RN
presented as means  standard error of the mean (error
sham operated group. #P  .05 vs TAO model group.
Table III. A, Effect of recombinant A (rA) box on blood
Groupa
Platelets Red blood ce
(108/mL) (109/mL)
Normal 7.23  0.46 6.32  0.44
Sham operation 7.46  0.57 6.28  0.32
TAO model 10.54  0.44b 6.19  0.76
rA box treatment
Low dose 9.11  0.69 6.34  0.55
High dose 7.68  0.54c 6.53  0.78
TAO, Thromboangiitis obliterans.
aValues are presented as means  standard error of the mean (n  8).
bP  .05 vs sham-operated group.
cP  .05 vs model group.IL-6, VCAM-1, and ICAM-1 in the femoral arteries of the sAO model, consistent with previous studies.3,23,37 More
mportantly, rA box treatment downregulated the expression
f proinflammatory cytokines to attenuate inflammatory re-
nscription polymerase chain reaction analysis of protein
lar adhesion molecule-1 (ICAM-1), and vascular cell
normal (nor), (b) sham-operated (sham), (c) thrombo-
) and (e) high-dose (rA box-HD) recombinant A (rA)
-6, ICAM-1, and VCAM-1 in rat femoral arteries by
lot of protein levels of IL-6, ICAM-1, and VCAM-1
ted as means  standard error of the mean (error bars);
operated group. #P  .05 vs TAO model group. ##P 
vels of IL-6, ICAM-1, and VCAM-1 for rat groups are
n  8. *P  .05 vs sham operated group. **P  .01 vs
counts in rats
Leukocytes Neutrophils Hemoglobin
(106/mL) (106/mL) (g/L)
4.88  0.23 1.06  0.27 130.36  5.89
5.12  0.36 1.09  0.15 128.72  6.43
5.09  0.59 1.12  0.18 130.08  8.67
5.01  0.63 1.16  0.19 131.37  5.62
4.98  0.24 1.11  0.13 132.45  6.24se tra
rcellu
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January 2013202 Kong et alrA box plays a protective role in reducing inflammatory medi-
ators by inhibiting HMGB1. However, rA box did not com-
pletely ameliorate the inflammatory responses compared with
controls, evenwith a high dose, which is probably because the
network is complex and other mediators are also involved.
This may explain why inflammatory-induced thrombosis was
not completely attenuated with high-dose rA box.
The mechanism may be that macrophages and endo-
thelial cells activated by sodium laurate can secrete
HMGB1 initiatively, whereas HMGB1 stimulates macro-
phages and endothelial cells to secrete IL-6, VCAM-1, and
ICAM-1, which, in turn, enhance HMGB1 expression by
macrophages and endothelial cells, thus amplifying the
inflammatory response. The function of HMGB1 was in-
hibited with rA box administration, which may explain the
decreased production of inflammatory factors, and inhibi-
tion of HMGB1 positive feedback may reduce the expres-
sion level of HMGB1.However, we did not study the effect
of RAGE antagonism on the progress of the disease and the
role of other receptors of HMGB1, such as TLR, which
Table III. B, Effect of recombinant A (rA) box on blood
Groupa
Prothrombin time Ac
(seconds)
Normal 38.13  1.72 39.
Sham operation 37.77  1.31 38.
TAO model 27.43  1.54b 22.
rA box treatment
Low dose 30.07  2.68 31.
High dose 36.89  1.56c 37.
PTT, Partial thromboplastin time; TAO, thromboangiitis obliterans.
aValues are presented as means  standard error of the mean (n  8).
bP  .05 vs sham operated group.
cP  .05 vs model group.
Fig 5. Plasma levels of thromboxane B2 (TXB2) and 6-keto-
prostaglandin F1- (6-K-PGF1-) and the TXB2/6-K-PGF1
ratio are shown in normal (nor), sham-operated (sham), thrombo-
angiitis obliterans (TAO) model, and low-dose (rA box-LD) and
high-dose (rA box-HD) recombinant A (rA) box-treated group.
Results are expressed in means standard error of the mean (error
bars); n 8. *P .05 vs sham operated group. **P .01 vs sham
operated group. #P  .05, vs TAO model group.need further investigation. iThe TAO model rats presented with a hypercoagulable
tate of blood and inflammatory thrombus within the lumen
f small vessels, as in a previous study.38 Moreover, TXA2 is
roduced by activated platelets and stimulates activation and
ggregation of new platelets. TXB2, its stable product, was
sed to reflect the level of TXA2. To further analyze the
rotectivemechanismof rAboxon theTAOrats, we explored
he effect of rA box on TXB2 and 6-K-PGF1-, the stable
ydrolysis product of PGI2, which inhibits platelet activation
nd dilate vessels. Normally, both are kept in homeostasis, but
he state was broken in TAO. As in a previous study,22 plasma
XB2 was obviously elevated in experimental TAO rats, but
he plasma6-K-PGF1- levelwas reduced.Treatmentwith rA
ox reverses the increased TXB2 level and the decreased
-K-PGF1- level in a dose-dependent manner; the ratio of
XB2/6-K-PGF1- was almost returned to normal. The
lood platelet count and fibrinogen level were reduced, and
rothrombin, thrombin, and activated partial thromboplastin
imes were close to normal compared with TAO rats; the
hange in the low-dose group was slight, which suggests that
he effect of rA box on hematology and coagulation may be
ose-dependent.
TAO is characterized by a highly cellular inflammatory
hrombus, because of inflammation-induced thrombo-
is.1,39 Here, we speculated that HMGB1 and its induced
nflammatory factors further activate platelets and exac-
rbate the endothelial injury and endothelial cell dys-
unction after the direct injury of sodium laurate, causing
he loss of physiologic anticoagulant and vasodilatory
roperties of the normal endothelium. rA box may re-
erse this by inhibiting the inflammatory response. Thus,
ndothelial cells may restore anticoagulant functions to
roduce thrombomodulin, which activates protein C,
nactivates thrombin and HMGB1, and accelerates anti-
hrombin III.40 The production of nitric oxide and PGI2
ay also be recovered. The downregulated activation of
latelets may cause reduced expression of cyclooxygen-
se-2; then, TXA2, which is the major platelet-derived
yclooxygenase-2 product, decreased accordingly. Over-
ll, rA box improved the hypercoagulable state of TAO
ats by regulating endothelial cell dysfunction and inhib-
ulation in rats
d PTT Thrombin time Fibrinogen level
ds) (seconds) (g/L)
2.89 24.82  1.79 3.02  0.17
3.04 23.97  2.03 3.16  0.25
3.12b 12.67  1.89b 5.87  0.48b
3.58c 18.72  2.34 4.64  0.31
4.65c 24.23  1.82c 3.58  0.39ccoag
tivate
(secon
01 
76 
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98 ting platelet aggregation.
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We have shown that HMGB1 and its receptor RAGE
are involved in the sodium laurate-induced TAO model in
rats and that rA box, as the antagonist of HMGB1, im-
proves the pathologic condition by inhibiting the release
and injury of inflammatory mediators and improving the
hypercoagulable state of blood. The findings provide new
experimental evidence for elucidating the pathogenesis of
TAO and define a new potential therapeutic target for
TAO. However, to explore the precise mechanism of
HMGB1 and RAGE in the development of TAO needs
further study at different times, with gene-knockdown
animals and endothelial cells, as well as macrophages.
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